Pembrolizumab showed an 89% objective response rate in unresectable desmoplastic melanoma, with a 37% complete response rate.

New clinical data reveals promising efficacy of VS-7375, a KRAS G12D inhibitor, in advanced lung cancer, highlighting its ...

Jason Luke, MD, FACP, discusses the mechanism of action of IMA203, a novel agent for the treatment of metastatic melanoma.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Abhinav Agrawal, MD, discusses findings from a multidisciplinary expert panel on endoscopic lung and lymph node biopsies that show how changes in biopsy methods have affected comprehensive biomarker ...

A phase 3 trial showed that alpelisib plus olaparib did not reduce the risk of progression or death in relapsed/refractory ...

Trifluridine/tipiracil shows potential in improving disease-free survival in colorectal cancer patients post-surgery, despite ...

A promising allogeneic CAR-T therapy has shown the potential to succeed in ovarian cancer where standard CAR-T treatments ...

New analysis reveals enzalutamide significantly outperforms darolutamide in treating metastatic hormone-sensitive prostate ...

New research reveals that many patients with low-risk thyroid cancer can safely skip postoperative radioiodine ablation, ...

Brexu-cel demonstrated efficacy and safety even in patients with B-cell acute lymphoblastic leukemia with central nervous ...

A digital app significantly enhances the quality of life for caregivers of stem cell transplant patients, reducing stress and ...